Youssef 2020 — Intravenous Aviptadil/VIP in Critical COVID-19

Journal of Translational Medicine

J. G. Youssef, et al.

Summary

VIP/aviptadil has been studied for pulmonary and immune signaling, including COVID-era respiratory failure research.

Study Details

Study Design

Clinical report / early clinical evidence

Indication

Critical COVID-19 respiratory failure

Intervention

Aviptadil / vasoactive intestinal peptide

Species

Human

Risk of Bias Assessment

Early COVID-era evidence; interpret cautiously